银杏二萜内酯葡胺联合硫酸氢氯吡格雷治疗缺血性脑卒中临床研
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R743.3

基金项目:


Clinical Study on Ginkgo Diterpene Lactone Glucamine Combined with Clopidogrel Bisulfate for Ischemic Stroke
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察银杏二萜内酯葡胺联合硫酸氢氯吡格雷治疗缺血性脑卒中的临床疗效。方法:选取74 例缺血性脑卒中患者,依照随机双盲法分成研究组和对照组各37 例。对照组给予硫酸氢氯吡格雷治疗,研究组在对照组基础上给予银杏二萜内酯葡胺治疗,2 组均治疗2 周。比较2 组临床疗效及不良反应发生率;比较2 组治疗前后白细胞介素-8 (IL-8)、肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hs-CRP)、纤维蛋白原(FIB) 水平及活化部分凝血活酶时间(APTT);采用美国国立卫生研究院卒中量表(NIHSS)、生活质量量表(QOL) 评估2 组治疗前后的神经功能缺损程度及生活质量。结果:研究组总有效率为91.89%,高于对照组的72.97% (P<0.05)。治疗后,2 组IL-8、TNF-α、hs-CRP 及FIB 水平均较治疗前降低(P<0.05),2 组APTT 均较治疗前延长(P<0.05);研究组IL-8、TNF-α、hs-CRP 及FIB 水平均低于对照组(P<0.05),APTT 长于对照组(P<0.05)。治疗后,2 组NIHSS 评分均较治疗前降低(P<0.05),食欲、睡眠、精神、日常生活评分均较治疗前升高(P<0.05);研究组NIHSS 评分低于对照组(P<0.05),食欲、睡眠、精神、日常生活评分均高于对照组(P<0.05)。研究组不良反应发生率为10.81%,对照组不良反应发生率为16.22%,2 组比较,差异无统计学意义(P>0.05)。结论:银杏二萜内酯葡胺联合硫酸氢氯吡格雷治疗缺血性脑卒中,可抑制机体炎症反应,改善患者的凝血功能与神经功能,提高其生活质量,且安全性好。

    Abstract:

    Abstract: Objective: To observe the clinical effect of ginkgo diterpene lactone glucamine combined with clopidogrel bisulfate for ischemic stroke. Methods:A total of 74 cases of patients with ischemic stroke were randomly divided into the study group and the control group according to the randomized double- blind method, with 37 cases in each group. The control group was treated with clopidogrel bisulfate, and the study group was additionally treated with ginkgo diterpene lactone glucamine based on the treatment of the control group. Both groups were treated for two weeks. The clinical effects and incidences of adverse reactions in the two groups were compared. Before and after treatment,the levels of interleukin-8 (IL- 8), tumor necrosis factor- α(TNF- α), hypersensitive C- reactive protein(hs- CRP) and fibrinogen(FIB) as well as the activated partial thromboplastin time(APTT) in the two groups were compared; the degree of neurological deficit and the quality of life in the two groups were evaluated by National Institutes of Health Stroke Scale(NIHSS) and Quality of Life Scale (QOL). Results:The total effective rate was 91.89% in the study group,higher than that of 72.97% in the control group(P< 0.05). After treatment,the levels of IL-8,TNF-α,hs-CRP and FIB in the two groups were decreased when compared with those before treatment(P<0.05),and APTT was prolonged(P<0.05);the levels of IL- 8,TNF- α,hs- CRP and FIB in the study group were lower than those in the control group(P<0.05),and the APTT was longer(P<0.05). After treatment,the NIHSS scores in the two groups were decreased when compared with those before treatment(P<0.05),and the scores of appetite,sleep,mentality and daily life in the two groups were increased(P<0.05);the NIHSS score in the study group was lower than that in the control group(P<0.05), and the scores of appetite, sleep, mentality and daily life were higher(P< 0.05). The incidence of adverse reactions was 10.81% in the study group and 16.22% in the control group,there being no significant difference between the two groups(P>0.05). Conclusion: The therapy of ginkgo diterpene lactone glucamine combined with clopidogrel bisulfate for ischemic stroke can inhibit systemic inflammatory response and improve coagulation function,neurological function and quality of life of patients,with good safety.

    参考文献
    相似文献
    引证文献
引用本文

石雷云.银杏二萜内酯葡胺联合硫酸氢氯吡格雷治疗缺血性脑卒中临床研[J].新中医,2022,54(2):42-45

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-01-22
  • 出版日期:
文章二维码